Last reviewed · How we verify

A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged >= 6 Months to < 18 Years

NCT00825162 Phase 4 COMPLETED Results posted

A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged \>= 6 Months to \< 18 Years

Details

Lead sponsorSeqirus
PhasePhase 4
StatusCOMPLETED
Enrolment1992
Start date2009-03
Completion2010-02

Conditions

Interventions

Primary outcomes

Countries

Australia